A Multidimensional Cross-Sectional Analysis of Coronavirus Disease 2019 Seroprevalence Among a Police Officer Cohort: The PoliCOV-19 Study.
anti-SARS-CoV-2 antibodies
coronavirus disease 2019
police officers
seroprevalence
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
20
09
2021
accepted:
13
10
2021
entrez:
10
12
2021
pubmed:
11
12
2021
medline:
11
12
2021
Statut:
epublish
Résumé
Protests and police fieldwork provide a high-exposure environment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. In this cross-sectional analysis, we investigated the seroprevalence among a police cohort, and sociodemographic, work, and health-related factors associated with seropositivity. Study participants were invited for serological testing of SARS-CoV-2 and to complete online questionnaires. Serum neutralization titers toward the wild-type SARS-CoV-2 spike protein (expressing D614G) and the Alpha and Beta variants were measured in seropositive study participants. A total of 978 police personnel representing 35% of the entire staff participated from February to March 2021. The seroprevalence was 12.9%. It varied by geographic region, ranged from 9% to 13.5% in 3 regions, including the city; and was 22% in Bernese Seeland/Jura with higher odds for seropositivity (odds ratio [OR], 2.38 [95% confidence interval {CI}, 1.28-4.44], The seroprevalence of anti-SARS-CoV-2 antibodies of police officers was comparable to that reported in the general population, suggesting that the personal protective equipment of the police is effective, and that household contacts are the leading transmission venues. The level of serum antibody titers, in particular that of anti-spike antibodies, correlated well with neutralization capacity. Low antibody titers acquired from natural infection were not effective against variants. NCT04643444.
Sections du résumé
BACKGROUND
BACKGROUND
Protests and police fieldwork provide a high-exposure environment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. In this cross-sectional analysis, we investigated the seroprevalence among a police cohort, and sociodemographic, work, and health-related factors associated with seropositivity.
METHODS
METHODS
Study participants were invited for serological testing of SARS-CoV-2 and to complete online questionnaires. Serum neutralization titers toward the wild-type SARS-CoV-2 spike protein (expressing D614G) and the Alpha and Beta variants were measured in seropositive study participants.
RESULTS
RESULTS
A total of 978 police personnel representing 35% of the entire staff participated from February to March 2021. The seroprevalence was 12.9%. It varied by geographic region, ranged from 9% to 13.5% in 3 regions, including the city; and was 22% in Bernese Seeland/Jura with higher odds for seropositivity (odds ratio [OR], 2.38 [95% confidence interval {CI}, 1.28-4.44],
CONCLUSIONS
CONCLUSIONS
The seroprevalence of anti-SARS-CoV-2 antibodies of police officers was comparable to that reported in the general population, suggesting that the personal protective equipment of the police is effective, and that household contacts are the leading transmission venues. The level of serum antibody titers, in particular that of anti-spike antibodies, correlated well with neutralization capacity. Low antibody titers acquired from natural infection were not effective against variants.
CLINICAL TRIALS REGISTRATION
BACKGROUND
NCT04643444.
Identifiants
pubmed: 34888394
doi: 10.1093/ofid/ofab524
pii: ofab524
pmc: PMC8651158
doi:
Banques de données
ClinicalTrials.gov
['NCT04643444']
Types de publication
Journal Article
Langues
eng
Pagination
ofab524Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Int J Public Health. 2020 Dec;65(9):1529-1548
pubmed: 33098441
BMJ. 2021 Jul 6;374:n1724
pubmed: 34230006
PLoS One. 2020 Nov 9;15(11):e0242124
pubmed: 33166369
Stat Med. 1985 Jan-Mar;4(1):87-90
pubmed: 3992076
J Clin Nurs. 2020 Jul;29(13-14):2047-2049
pubmed: 32281158
Ann Glob Health. 2020 Jul 06;86(1):76
pubmed: 32704481
Clin Infect Dis. 2021 Jul 30;73(Suppl 2):S138-S145
pubmed: 33045075
JAMA Netw Open. 2020 Dec 1;3(12):e2031756
pubmed: 33315116
Psychiatry Res. 2020 Jul;289:113046
pubmed: 32387794
J Clin Med. 2020 Oct 11;9(10):
pubmed: 33050603
Infect Dis Ther. 2021 Dec;10(4):2381-2397
pubmed: 34368915
Front Microbiol. 2020 Oct 19;11:584251
pubmed: 33193227
J Virol Methods. 2021 Nov;297:114271
pubmed: 34461153
J Infect Dis. 2020 Jun 29;222(2):206-213
pubmed: 32427334
PLoS One. 2020 Apr 28;15(4):e0232452
pubmed: 32343747
PLoS One. 2020 Jan 27;15(1):e0227699
pubmed: 31986165
J Coll Physicians Surg Pak. 2020 Jul;30(7):735-739
pubmed: 32811605
Sci Rep. 2019 Feb 20;9(1):2348
pubmed: 30787335
J Occup Environ Med. 2015 May;57(5):501-8
pubmed: 25816216
Nature. 2021 Jul;595(7869):707-712
pubmed: 34098568
Am Rev Respir Dis. 1968 Aug;98(2):297-300
pubmed: 5667756
Am J Emerg Med. 2020 Dec;38(12):2753-2755
pubmed: 32402499
Emerg Infect Dis. 2021 Mar;27(3):796-804
pubmed: 33493106
BMJ. 2020 May 7;369:m1712
pubmed: 32381644
Clin Microbiol Infect. 2021 Jul;27(7):981-986
pubmed: 33975005